Qiagen N.V.

NYSE:QGEN 株式レポート

時価総額：US$7.3b

Qiagen 将来の成長

Future 基準チェック /16

Qiagen利益と収益がそれぞれ年間12.4%と6.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に13.4% 11.9%なると予測されています。

主要情報

12.4%

収益成長率

11.91%

EPS成長率

Life Sciences 収益成長17.6%
収益成長率6.1%
将来の株主資本利益率13.41%
アナリストカバレッジ

Good

最終更新日18 May 2026

今後の成長に関する最新情報

分析記事 • Nov 08

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...
分析記事 • Aug 08

Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...

Recent updates

新しいナラティブ • May 15

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Apr 30

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?
ナラティブの更新 • Apr 29

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion

Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.
ナラティブの更新 • Apr 10

QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns

Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.
ナラティブの更新 • Mar 27

QGEN: Possible Sale Prospects Are Expected To Drive Future Returns

The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.
ナラティブの更新 • Mar 12

QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns

The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.
ナラティブの更新 • Feb 25

QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside

Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.
ナラティブの更新 • Feb 11

QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks

Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.
ナラティブの更新 • Jan 28

QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition

Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.
Seeking Alpha • Jan 27

Qiagen: Takeover Optionality With A High-Quality Consumables Platform

Summary QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there’s renewed takeover speculation after reports that show they’re weighing strategic options. QGEN’s potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed. QGEN’s portfolio with Parse Biosciences adds single-cell sequencing scale, while 2026 automation launches would further deepen its differentiated workflow. I think QGEN now makes much more sense given the renewed M&A interest. But if deal talks fail or rumors cool, shares could de-rate, so my “Buy” rating is explicitly speculative. Read the full article on Seeking Alpha
ナラティブの更新 • Jan 08

QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions

Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).
分析記事 • Jan 07

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued

Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...
ナラティブの更新 • Dec 14

QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead

Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.
ナラティブの更新 • Nov 29

QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms

Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.
ナラティブの更新 • Nov 15

QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside

Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.
分析記事 • Nov 08

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...
ナラティブの更新 • Oct 31

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.
ナラティブの更新 • Oct 17

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.
ナラティブの更新 • Oct 03

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.
ナラティブの更新 • Sep 04

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.
分析記事 • Sep 02

Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality

Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...
分析記事 • Aug 08

Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...
分析記事 • Aug 05

Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...
Seeking Alpha • Feb 25

Qiagen N.V.: Some Clarity Needed Before Buying The Dip

Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking Alpha

業績と収益の成長予測

NYSE:QGEN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20282,40657255778312
12/31/20272,27246752974316
12/31/20262,15540649570516
3/31/20262,099402404615N/A
12/31/20252,090425447654N/A
9/30/20252,071405473658N/A
6/30/20252,040373496675N/A
3/31/20252,00394503680N/A
12/31/20241,97884502674N/A
9/30/20241,96693460633N/A
6/30/20241,94073405576N/A
3/31/20241,939337358521N/A
12/31/20231,965341297459N/A
9/30/20231,954332275432N/A
6/30/20231,978337376519N/A
3/31/20231,999353430580N/A
12/31/20222,142423566715N/A
9/30/20222,226488660826N/A
6/30/20222,261539580770N/A
3/31/20222,313563556755N/A
12/31/20212,252513432639N/A
9/30/20212,240311516745N/A
6/30/20212,190480337592N/A
3/31/20212,065449239571N/A
12/31/20201,870359154458N/A
9/30/20201,71319110298N/A
6/30/20201,61214108333N/A
3/31/20201,550-31152302N/A
12/31/20191,526-41N/A331N/A
9/30/20191,516-25N/A332N/A
6/30/20191,511196N/A342N/A
3/31/20191,507188N/A356N/A
12/31/20181,502190N/A359N/A
9/30/20181,49690N/A325N/A
6/30/20181,48278N/A324N/A
3/31/20181,45355N/A275N/A
12/31/20171,41840N/A287N/A
9/30/20171,38789N/A311N/A
6/30/20171,36275N/A323N/A
3/31/20171,34782N/A353N/A
12/31/20161,33880N/A342N/A
9/30/20161,320123N/A328N/A
6/30/20161,296123N/A331N/A
3/31/20161,281126N/A303N/A
12/31/20151,281130N/A317N/A
9/30/20151,293104N/A310N/A
6/30/20151,315105N/A303N/A

アナリストによる今後の成長予測

収入対貯蓄率: QGENの予測収益成長率 (年間12.4% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: QGENの収益 ( 12.4% ) US市場 ( 16.8% ) よりも低い成長が予測されています。

高成長収益: QGENの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: QGENの収益 ( 6.1% ) US市場 ( 11.7% ) よりも低い成長が予測されています。

高い収益成長: QGENの収益 ( 6.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: QGENの 自己資本利益率 は、3年後には低くなると予測されています ( 13.4 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/24 16:52
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Qiagen N.V. 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。42

アナリスト機関
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Charles ButlerBarclays